RB1 and neoplasm: Thus, current research is moving towards marking additional elements of the p53 and Rb pathways, like the negative p53 regulator MDM2 or the CDK4/6 that inhibits Rb, for potential use as tumor-agnostic biomarkers [94,95,96].